Drugs / Optimized neoantigen synthetic long peptide vaccine
Optimized neoantigen synthetic long peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05111353 | Dec 2022 → Nov 2025 | malignant pancreatic neoplasm | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Optimized neoantigen synthetic long peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05111353 ↗ |
| Modality | Vaccine | “Biological: Optimized neoantigen synthetic long peptide vaccine” NCT05111353 ↗ |
| Route | Intramuscular | “Peptide and poly-ICLC will be administered intramuscularly” NCT05111353 ↗ |